Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial

Prespecified analysis (n=16 361 with metabolic syndrome) found in these high-risk patients, compared with placebo, evolocumab significantly reduced LDL cholesterol and risk of CV events without increasing risk of safety events, new-onset diabetes, or worsening glycaemic control.

JAMA Cardiology